On the other hand, because TP53, ATRX and IDH mutations are early events in gliomas [23], protein expression assessed by IHC is either diffusely lost (ATRX) or diffusely present (protein IDH1 R132H, p53) in tumor cells (Figure 5). Here, ATRX is linked to central nervous system cancer.